---
title: "BrightGene: Net profit in the third quarter was 33.1468 million yuan, a year-on-year decrease of 53.34%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263510700.md"
description: "BrightGene announced that its revenue for the third quarter was 337 million yuan, a year-on-year increase of 5.54%; net profit was 33.1468 million yuan, a year-on-year decrease of 53.34%. Revenue for the first three quarters was 874 million yuan, a year-on-year decrease of 10.50%; net profit was 5.032 million yuan, a year-on-year decrease of 71.64%"
datetime: "2025-10-30T11:54:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263510700.md)
  - [en](https://longbridge.com/en/news/263510700.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263510700.md)
---

# BrightGene: Net profit in the third quarter was 33.1468 million yuan, a year-on-year decrease of 53.34%

BrightGene announced that its revenue for the third quarter was 337 million yuan, a year-on-year increase of 5.54%; net profit was 33.1468 million yuan, a year-on-year decrease of 53.34%. Revenue for the first three quarters was 874 million yuan, a year-on-year decrease of 10.50%; net profit was 50.32 million yuan, a year-on-year decrease of 71.64%

### Related Stocks

- [688166.CN](https://longbridge.com/en/quote/688166.CN.md)

## Related News & Research

- [02:32 ETBrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States](https://longbridge.com/en/news/280422627.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Orion Pharma to reveal initial results from Phase 1/2 TEADES study of ODM-212 at 2026 ASCO® Meeting.](https://longbridge.com/en/news/287177935.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)